Results from the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) trial will be presented at 2:15 p.m. Sunday in W-3001 (West, Level 3). Itamar Raz, MD, the study’s co-principal investigator, discusses the study’s significance.
News Updates from the 83rd Scientific Sessions
Results from the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) trial will be presented at 2:15 p.m. Sunday in W-3001 (West, Level 3). Itamar Raz, MD, the study’s co-principal investigator, discusses the study’s significance.
